WO2007038855A1 - Gel medical - Google Patents

Gel medical Download PDF

Info

Publication number
WO2007038855A1
WO2007038855A1 PCT/CA2006/001599 CA2006001599W WO2007038855A1 WO 2007038855 A1 WO2007038855 A1 WO 2007038855A1 CA 2006001599 W CA2006001599 W CA 2006001599W WO 2007038855 A1 WO2007038855 A1 WO 2007038855A1
Authority
WO
WIPO (PCT)
Prior art keywords
medical gel
gel
medical
present
cellulose
Prior art date
Application number
PCT/CA2006/001599
Other languages
English (en)
Inventor
Terence O'reilly
George Botos
Jay Herman
Original Assignee
Sigmacon Medical Products Corporation
Germiphene Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigmacon Medical Products Corporation, Germiphene Corporation filed Critical Sigmacon Medical Products Corporation
Publication of WO2007038855A1 publication Critical patent/WO2007038855A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A61K8/416—Quaternary ammonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/43—Guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
    • A61K8/8141—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • A61K8/8147—Homopolymers or copolymers of acids; Metal or ammonium salts thereof, e.g. crotonic acid, (meth)acrylic acid; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/005—Antimicrobial preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations

Definitions

  • This invention relates to medical gels and more specifically to medical gels having antimicrobial properties.
  • Coupling media are often used for light-based cosmetic cutaneous procedures and ultrasound.
  • ointment-like gels have been applied to the body surface as coupling media to ensure such contact.
  • materials of this type must be used with care to ensure that there are no air bubbles between the acoustic device and the body surface. They may be impracticable or unsuitable for application in some cases, for example where the body surface is cut or abraded or body organs exposed during surgery are to be visualised and are frequently found to transmit sound or light inefficiently.
  • Most known gels for non-critical applications are water-base gels containing a cellulose or acrylic thickener.
  • U.S. Patent No. 4,002,221 describes the use of a gel containing a mixture of a cellulose derivate polymer and an acrylic polymer.
  • Other ingredients proposed are propylene glycol as humectants and wetting agents, preservatives (parabens), and a Citric Acid/Potassium Citrate buffer.
  • the recommended pH range is 6.5-7.5 and the recommended viscosity range is 13000 - 60000 cPs.
  • U.S. Patent No. 5,178,143 teaches an electrically conductive gel, recommended especially for TENS (Transcutaneous Electrical Nerve Stimulation) systems.
  • the gel of U.S. Patent No. 5,178,143 comprises a custom polymer.
  • Health Canada Health Products and Food Branch
  • a medical gel comprising a solvent, a thickener and an antimicrobial agent.
  • the solvent is water
  • the thickener is Hydroxyethyl Cellulose
  • the antimicrobial agent is benzalkonium chloride.
  • the medical gel also comprises glycerine, Polyethylene Glycol with an average molecular weight of 3350 Dalton and menthol.
  • a medical gel that has antimicrobial and/or antibacterial properties is provided.
  • the gels of the present invention are useful as coupling and lubricating media for light-based cosmetic cutaneous procedures, including but not limited to hair removal, laser peel for wrinkles, red-nose syndrome, tattoo removal, removal of leg veins and age spots removal.
  • the gels of the present invention are also useful as ultrasound coupling and lubricating media used in the examination of superficial structures of the body, in postoperative or intraoperative ultrasonic examinations as well as preoperative and screening examinations and may be directly applied to the skin.
  • Another use of the gels of the present invention is a general skin cleanser or specifically for wounds, cuts, minor burns and insect bites.
  • the medical gel comprises a solvent, a thickener and an antimicrobial agent.
  • the solvent is preferably water.
  • the thickener can be any thickener known in the art used for creating a gel in cooperation with a solvent.
  • the thickener is selected from the group consisting of polyacrylate (carbopol), a cellulose derivate such as hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropylmethyl cellulose or carboxymethyl cellulose, xanthan gum, and mixtures thereof.
  • the cellulose derivate is hydroxyethyl cellulose and is present in the gel at 0.1% to 5% w/w, preferably at 2% w/w.
  • the hydroxyethyl cellulose is preferably a higher molecular weight grade hydroxyethyl cellulose, such as NatrosolTM 250 HHR, and is more preferably present at 1% w/w.
  • a mixture of xanthan gum, such as RhodigelTM, and carboxymethyl cellulose, such as CMC 7H3SXF may be added.
  • the xanthan gum is present at 0.25% w/w and the carboxymethyl cellulose is present at 0.25% w/w.
  • the antimicrobial agent is selected from the group consisting of quaternary ammonium compounds, triclosan, hydrogen peroxide and hydrogen peroxide generating compounds. It will be understood, however, by a person skilled in the art that any antimicrobial agent may be used that would be stable and active in a medical gel and is suitable for application to the skin.
  • the antimicrobial agent is a quaternary ammonium compounds selected from the group consisting of benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, chlorhexidine acetate and cetyl pyridinum chloride.
  • the antimicrobial agent is chosen, and at a concentration, preferably to not only maintain antibicrobial efficacy of the gel but to actively decrease the risk of transmission of bacteria , fungi and viruses from one patient to another.
  • Topical antimicrobials are preferable to antibiotics since antibiotics can generate bacterial resistance.
  • Antibiotic-resistant bacteria and viruses are of particular concern generally in the medical field and particularly in hospitals and in operatory settings.
  • Antimicrobials, such as quaternary ammonium compounds have the advantage of limited toxicity, and a chemical mechanism of action. Without being bound to any theory, it modifies the membrane cell permeability on bacteria and fungi and denatures the protein structure of small enveloped viruses. Therefore, the risk of generating resistance is minimal.
  • benzalkonium chloride is the antimicrobial agent and is present in the medical gel at 0.04% to 2.0% w/w, preferably at 0.1% w/w.
  • a bioadhesive is also present in the medical gel.
  • the bioadhesive may be any bioadhesive that increases adherence to the skin and reduces the elasticity of the gel. This may be desirable in some applications since viscoelastic gels are difficult to apply on a vertical surface as they have poor adherence.
  • the bioadhesive is preferably selected from the group consisting of polyvinylpirrolidones of different molecular weight, cellulose derivates and xanthan gum.
  • the bioadhesive is polyvinylpyrrolidone, such as PlasdoneTM C30, and is present in the medical gel at 0.1% to 5% w/w, preferably at 0.3%.
  • the bioadhesive is a mixture of xanthan gum and carboxymethyl cellulose.
  • the xanthan gum is present in the medical gel at 0.25% w/w, and the carboxymethyl cellulose is present at 0.25% w/w.
  • the xanthan gum may be, for example, RhodigelTM, and the carboxymethyl cellulose may be, for example, CMC 7H3SXF or CMC-7MF. This mixture may also serve as a thickener.
  • the medical gel further comprises at least one of menthol benzocaine, lidocaine and camphor. These compounds may be used to provide any one of a general cooling effect to the skin, some anaesthetic effect and an odour masking effect.
  • menthol is present in the gel at 0.01% to 10% w/w, preferably, at 0.03% w/w.
  • the gel further comprises at least one of glycerine, propylene glycol, polyethylene oxide with a molecular weight of 200 to 20,000, preferably a molecular weight of 400 to 3500.
  • Glycerin is preferably present at 0.01% to 30% w/w in the gel to prevent the medical gel from freezing when stored in a refrigerator.
  • a cold gel is desirable, particularly for some laser procedures to help absorb the heat generated by the procedure. Cold storage may further help preserve the shelf-life of the medical gel.
  • Glycerin also serves as a moisterizer and humectant for the skin.
  • PEG is also preferably present as a solvent, bioadhesive, rheology modifier and a humectant.
  • High molecular weight polyethylene glycol like PEG 3350
  • PEG solutions exhibit Newtonian rheology (the viscosity is independent of shear) below melting point, thus reducing the drop in viscosity upon application on the skin.
  • PEG 3350 is present in the medical gel at 0.1% to 30% w/w.
  • glycerin and PEG 3350 are each present in the medical gel at 5% w/w.
  • PEG 3350 is present in the medical gel at 3% to 5% w/w, and glycerine is not present.
  • the medical gel comprises (w/w) glycerin USP at 5%, CarbowaxTM 3350 PEG at 5%, NatrosolTM 250H USP at 2%, benzalkonium chloride at 0.1%, menthol USP at 0.03%, PlasdoneTM C30 at 0.3% and water as the solvent at 87.57%.
  • the medical gel comprises (w/w) CarbowaxTM 3350 PEG at 3% to 5%, NatrosolTM 250 HHR at 1%, benzalkonium chloride at 0.1%, RhodigelTM at 0.25%, CMC 7H3SXF at 0.25%, methol at 0.03%, and water as the solvent making up the balance.
  • This embodiment of the medical gel contains 0.1% Benzalkonium Chloride, which is considered as an efficient skin antiseptic and has a minimal risk of producing allergic reaction.
  • the preferred embodiment also contains a thickener, and a solvent, in accordance with the invention as described above.
  • the preferred embodiment in the following example is a medical gel comprising (w/w) deionised water at 87.545%, glycerine at 5.0%, NatrosolTM 250H at 2.0%, benzalkonium chloride at 0.1%, methol at 0.03%, PlasdoneTM C30 at 0.3%, and CarbowaxTM 3350 PEG at 5%.
  • a loopful from recently revived stock culture of Serratia marcescens was aseptically inoculated in TSA plate and incubated at 25° C for 24 hrs. After incubation, the purity of the culture was checked by Gram staining.
  • the culture was transferred in 10 ml TSB and incubated it at 25° C for 24 hrs.
  • the cells then were harvested by centrifugation (30 minute at approx. 2000 RPM), washed and re- suspended in sterile saline TS. The transferring and harvesting procedure was repeated three times.
  • the inoculum was collected in a tube containing 10 ml sterile saline to obtain a count of about 1 x 10 8 CFU/ml.
  • Neutralizing Solution The neutralizing solution used contained 0.75% Azolectin, 5% Tw een 60, and 0.1 % Sodium Thiosulphate.
  • Media Four types of media were used for plating - Tryptic Soy agar (4%), Sabouraud Dextrose agar (6.5%), Mac Conkey agar (5%), and Blood agar (4%).
  • Each skin sample and the tip of the laser guide were then swabbed using a sterile swab and buffer solution, and transferred to 100 ml Neutralizing Solution. 1 ml from each sample was then plated on four different media (Tryptic Soy Agar, Sabouraud Dextrose Agar, Blood Agar, Mac Conkey Agar) in duplicate and incubated for seven days at 30 0 C.
  • MIC Minimum Inhibitory Concentration
  • test results are consistent with known findings that ex-vivo test on pigskin results in a broader range of standard deviation than in- vitro test, with hide-to-hide and other inherent procedure variations; however, overall the test showed clear efficacy in the given testing condition (five-minute contact time) against the test bacteria.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne un gel anti-microbien médical utile comme support d'accouplement et lubrifiant pour des procédures cutanées à base de rayonnements ou d'ultrasons et comprenant un solvant, un épaississant et un agent anti-microbien et, de préférence un bioadhésif et un humectant.
PCT/CA2006/001599 2005-10-04 2006-09-28 Gel medical WO2007038855A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US72299605P 2005-10-04 2005-10-04
US60/722,996 2005-10-04
US77335406P 2006-02-15 2006-02-15
US60/773,354 2006-02-15

Publications (1)

Publication Number Publication Date
WO2007038855A1 true WO2007038855A1 (fr) 2007-04-12

Family

ID=37905929

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2006/001599 WO2007038855A1 (fr) 2005-10-04 2006-09-28 Gel medical

Country Status (1)

Country Link
WO (1) WO2007038855A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050447A2 (fr) 2007-10-19 2009-04-23 Magenta Trading Limited Produits pour la peau à base d'eau
WO2009076718A1 (fr) * 2007-12-17 2009-06-25 Novapharm Research (Australia) Pty Ltd Composition viricide
WO2009083846A2 (fr) * 2007-12-20 2009-07-09 Koninklijke Philips Electronics N.V. Support de couplage optique
FR2936156A1 (fr) * 2008-09-23 2010-03-26 Frederic Bosler Gel appropie a la transmission d'ondes ultrasoniques, procede de fabrication dudit gel et poche le contenant
WO2012009794A1 (fr) * 2010-07-19 2012-01-26 Brusells Ventures Corp. Composition de gel médical antimicrobien comprenant de l'hydroxyéthylcellulose éthérifiée
WO2012082658A2 (fr) * 2010-12-13 2012-06-21 Loren Rauch Gel ou milieu de couplage antimicrobien de transmission d'ultrasons
CN102675793A (zh) * 2012-05-04 2012-09-19 浦江县鑫平进出口有限公司 一种蓝色半透明鼻涕胶及其制备方法
CN102875943A (zh) * 2012-05-04 2013-01-16 浦江县鑫平进出口有限公司 一种红色半透明鼻涕胶及其制备方法
WO2013064805A1 (fr) * 2011-10-31 2013-05-10 The Premiere Polish Company Limited Composition de soins personnels et dispositif d'administration de celle-ci
WO2016185811A1 (fr) * 2015-05-20 2016-11-24 富士フイルム株式会社 Support de contact de type revêtement pour le diagnostic par ultrasons
WO2017075320A1 (fr) * 2015-10-31 2017-05-04 Dermalink Technologies, Inc. Adhésifs cutanés, compositions antimicrobiennes, articles et procédés d'utilisation de ceux-ci
WO2017117650A1 (fr) * 2016-01-10 2017-07-13 Smilesonica Inc Gel à ultrasons à viscosité et stabilité modifiées
US10308897B2 (en) 2017-04-24 2019-06-04 Gpcp Ip Holdings Llc Alkaline sanitizing soap preparations containing quaternary ammonium chloride agents
CN110559457A (zh) * 2019-09-05 2019-12-13 广州广工技术开发有限公司 一种制备医用超声耦合剂无菌产品可安全使用的方法
US11478435B2 (en) 2017-02-22 2022-10-25 Smilesonica Inc. Artificial saliva, related methods, and uses
IT202100031556A1 (it) * 2021-12-16 2023-06-16 Claudio Bandini Gel ecografico

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2770402A1 (fr) * 1997-11-05 1999-05-07 Pierre Cohen Gel de conduction ultrasonore pour echographie, doppler et examens electrocardiographiques presentant des proprietes antiseptiques
US20020061864A1 (en) * 1994-09-22 2002-05-23 Geda International Marketing Company Ltd. Antiseptic spermicidal composition and means for its application

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020061864A1 (en) * 1994-09-22 2002-05-23 Geda International Marketing Company Ltd. Antiseptic spermicidal composition and means for its application
FR2770402A1 (fr) * 1997-11-05 1999-05-07 Pierre Cohen Gel de conduction ultrasonore pour echographie, doppler et examens electrocardiographiques presentant des proprietes antiseptiques

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009050447A2 (fr) 2007-10-19 2009-04-23 Magenta Trading Limited Produits pour la peau à base d'eau
WO2009076718A1 (fr) * 2007-12-17 2009-06-25 Novapharm Research (Australia) Pty Ltd Composition viricide
US10010072B2 (en) 2007-12-17 2018-07-03 Novapharm Research (Australia) Pty Ltd. Viricidal composition
WO2009083846A3 (fr) * 2007-12-20 2009-08-27 Koninklijke Philips Electronics N.V. Support de couplage optique
WO2009083846A2 (fr) * 2007-12-20 2009-07-09 Koninklijke Philips Electronics N.V. Support de couplage optique
FR2936156A1 (fr) * 2008-09-23 2010-03-26 Frederic Bosler Gel appropie a la transmission d'ondes ultrasoniques, procede de fabrication dudit gel et poche le contenant
WO2010034901A2 (fr) 2008-09-23 2010-04-01 Bosler Frederic Gel approprié à la transmission d'ondes ultrasoniques, procédé de fabrication dudit gel et poche le contenant
WO2010034901A3 (fr) * 2008-09-23 2010-10-07 Bosler Frederic Gel approprié à la transmission d'ondes ultrasoniques, procédé de fabrication dudit gel et poche le contenant
WO2012009794A1 (fr) * 2010-07-19 2012-01-26 Brusells Ventures Corp. Composition de gel médical antimicrobien comprenant de l'hydroxyéthylcellulose éthérifiée
US8618175B2 (en) 2010-07-19 2013-12-31 Brussels Ventures Corp. Ultrasound medical gel composition etherified hydroxyethylcellulose
AU2011282427A8 (en) * 2010-07-19 2014-10-09 Brusells Ventures Corp. Antimicrobial medical gel composition comprising etherified hydroxyethylcellulose
AU2011282427B2 (en) * 2010-07-19 2014-09-18 Brusells Ventures Corp. Antimicrobial medical gel composition comprising etherified hydroxyethylcellulose
EP2595480A4 (fr) * 2010-07-19 2014-06-18 Brusells Ventures Corp Composition de gel médical antimicrobien comprenant de l'hydroxyéthylcellulose éthérifiée
EP2595480A1 (fr) * 2010-07-19 2013-05-29 Brusells Ventures Corp. Composition de gel médical antimicrobien comprenant de l'hydroxyéthylcellulose éthérifiée
WO2012082658A2 (fr) * 2010-12-13 2012-06-21 Loren Rauch Gel ou milieu de couplage antimicrobien de transmission d'ultrasons
WO2012082658A3 (fr) * 2010-12-13 2012-09-07 Loren Rauch Gel ou milieu de couplage antimicrobien de transmission d'ultrasons
WO2013064805A1 (fr) * 2011-10-31 2013-05-10 The Premiere Polish Company Limited Composition de soins personnels et dispositif d'administration de celle-ci
GB2521488A (en) * 2011-10-31 2015-06-24 Premiere Polish Company Ltd Personal care composition and a device for dispensing the same
CN102875943B (zh) * 2012-05-04 2014-03-05 浦江县鑫平进出口有限公司 一种红色半透明鼻涕胶及其制备方法
CN102875943A (zh) * 2012-05-04 2013-01-16 浦江县鑫平进出口有限公司 一种红色半透明鼻涕胶及其制备方法
CN102675793A (zh) * 2012-05-04 2012-09-19 浦江县鑫平进出口有限公司 一种蓝色半透明鼻涕胶及其制备方法
CN107530050A (zh) * 2015-05-20 2018-01-02 富士胶片株式会社 超声波诊断用涂布型接触介质
JPWO2016185811A1 (ja) * 2015-05-20 2018-02-22 富士フイルム株式会社 超音波診断用の塗布型接触媒体
WO2016185811A1 (fr) * 2015-05-20 2016-11-24 富士フイルム株式会社 Support de contact de type revêtement pour le diagnostic par ultrasons
WO2017075320A1 (fr) * 2015-10-31 2017-05-04 Dermalink Technologies, Inc. Adhésifs cutanés, compositions antimicrobiennes, articles et procédés d'utilisation de ceux-ci
WO2017117650A1 (fr) * 2016-01-10 2017-07-13 Smilesonica Inc Gel à ultrasons à viscosité et stabilité modifiées
US11478435B2 (en) 2017-02-22 2022-10-25 Smilesonica Inc. Artificial saliva, related methods, and uses
US10308897B2 (en) 2017-04-24 2019-06-04 Gpcp Ip Holdings Llc Alkaline sanitizing soap preparations containing quaternary ammonium chloride agents
US10920174B2 (en) 2017-04-24 2021-02-16 Gpcp Ip Holdings Llc Sanitizing soap preparations comprising an amphoteric/cationic surfactant mixture
US11884896B2 (en) 2017-04-24 2024-01-30 Gpcp Ip Holdings Llc Sanitizing soap preparation comprising a benzalkonium chloride/alkyl trimonium cationic surfactant combination
CN110559457A (zh) * 2019-09-05 2019-12-13 广州广工技术开发有限公司 一种制备医用超声耦合剂无菌产品可安全使用的方法
CN110559457B (zh) * 2019-09-05 2020-06-12 广州广工技术开发有限公司 一种制备医用超声耦合剂无菌产品可安全使用的方法
IT202100031556A1 (it) * 2021-12-16 2023-06-16 Claudio Bandini Gel ecografico
WO2023111973A1 (fr) * 2021-12-16 2023-06-22 Bandini Claudio Gel à ultrasons

Similar Documents

Publication Publication Date Title
WO2007038855A1 (fr) Gel medical
US11510960B2 (en) Biofilm disrupting composition for use on chronic wounds
JP7118022B2 (ja) 細菌性バイオフィルムを除去するためのセアプローゼの使用
CN104274490B (zh) 包括银离子源和薄荷醇的抗菌组合物及其用途
EP2283130B1 (fr) Compositions anti-biofilm à base de dispersin B (MD), 5-fluorouracile, désoxyribonuclease I et la protéinase K et leur utilisations
EP3245871A1 (fr) Compositions antimicrobiennes
EP1887864B1 (fr) Composition pour preparer un patient a une intervention chirurgicale
KR20070040332A (ko) 다중양이온성 항균 치료
Echols et al. Role of antiseptics in the prevention of surgical site infections
DK3035915T3 (en) Composition, in particular in the form of a gel, and its use
CN104095876B (zh) 一种稳定的医用防护冲洗液及其制备方法
WO2003082304A1 (fr) Compositions antimicrobiennes et leurs methodes d'utilisation
Dzubow et al. Comparison of preoperative skin preparations for the face
JP3577113B2 (ja) 皮膚外用剤
KR102096257B1 (ko) 폴리비닐피롤리돈 및 유니티올을 포함하는 방부제 조성물 및 조성물의 용도
Pasolini et al. Using cyanoacrylate microbial sealant for skin preparation prior to the placement of intravenous catheters in horses
Horaitou Comparative study of Povidone-Iodine and Chlorhexidine used in surgical procedures of dogs and cats.
US20150064129A1 (en) Wound healing composition
Stashak Wound infection: contributing factors and selected techniques for prevention.
Qutieshat et al. Antimicrobial Irrigation Solutions in Root Canal Treatment: A Glance at the Past, the Present, and the Future
Marchionatti The Preparation of the Surgical Site and the Disinfection of the Surgeon's Hands-Standards and their Implementation in a Field Setting
BR102020004724A2 (pt) Formulações tópicas de uso na assepsia de campo cirúrgico de animais domésticos à base de hidrocloreto de poli-hexametileno associadas ou não à clorexidina.
Kudavidanage et al. Comparison of Three Skin Disinfectant Solutions used for Skin Preparation prior to Spinal and Epidural Anaesthetic Procedures in Parturients at De Soyza Maternity Hospital and Castle Street Hospital for Women
Tuama et al. Early tangential excision with guidance of gentian violate application
JP2011079791A (ja) 皮膚消毒用外用剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06790763

Country of ref document: EP

Kind code of ref document: A1